Trials / Completed
CompletedNCT07376265
A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients
Comparative Effectiveness of Sacubitril/Valsartan vs ACEi/ARB in HFrEF Patients: Real Heart PT
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,249 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a retrospective, observational, comparative cohort study using secondary data from electronic health records (EHR) from a local health unit that provides primary, secondary and tertiary care to a resident population in northern Portugal. The study aimed to assess the comparative effectiveness of sacubitril/valsartan (SAC/VAL) versus angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients with heart failure with reduced ejection fraction (HFrEF).
Conditions
Timeline
- Start date
- 2023-10-20
- Primary completion
- 2024-04-11
- Completion
- 2024-04-11
- First posted
- 2026-01-29
- Last updated
- 2026-02-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07376265. Inclusion in this directory is not an endorsement.